Vitamin E supplements in asthma: a parallel group randomised placebo controlled trial

P J K Pearson, S A Lewis, J Britton, A Fogarty

Background: Increased dietary vitamin E intake is associated with a reduced incidence of asthma, and combinations of antioxidant supplements including vitamin E are effective in reducing ozone induced bronchoconstriction. A study was undertaken to investigate the effect of supplementation with vitamin E for 6 weeks on bronchial hyperresponsiveness in atopic adults with asthma.

Methods: 72 participants from a clinical trial register of adults with asthma were randomised to receive 500 mg natural vitamin E or matched placebo for 6 weeks in a placebo controlled, double blind parallel group clinical trial. Inclusion criteria included age 18–60 years, maintenance treatment of at least one dose of inhaled corticosteroid per day, a positive skin prick test to one of three common allergens, and bronchial hyperresponsiveness to methacholine (defined as a dose provoking a 20% fall in forced expiratory volume in 1 second (FEV1) (PD20) of 12.25 μmol). Secondary outcomes were FEV1, forced vital capacity, mean morning and evening peak flow, symptom scores, bronchodilator use, and serum immunoglobulin E levels.

Results: In the primary intention to treat analysis the change in PD20 was similar in the vitamin E and placebo groups with a mean difference of +0.25 doubling doses of methacholine (95% confidence interval −0.67 to +1.16 greater with vitamin E). There was no effect of vitamin E supplementation on any other measure of asthma control, either in the intention to treat or per protocol analysis. There was also no effect of vitamin E supplementation on serum immunoglobulin levels.

Conclusion: Dietary supplementation with vitamin E adds no benefit to current standard treatment in adults with mild to moderate asthma.

Epidemiological evidence suggests that antioxidants have a significant effect on the incidence and severity of asthma. Both dietary and biochemical measures of vitamin E are lower in adults with asthma than in those without the disease, while higher dietary vitamin E intake is associated with a reduced incidence of asthma. In addition, four randomised controlled trials of a combination of antioxidant supplements including vitamin E have shown a reduction in ozone induced bronchoconstriction in those with and without a diagnosis of asthma. Since these findings suggest that supplementation with vitamin E may also have a beneficial effect on asthma management, we performed a randomised placebo controlled trial of the effect of 6 weeks of regular supplementation with vitamin E on clinical control of asthma.

METHODS

Participants

Participants aged 18–60 with physician diagnosed asthma and using at least one dose of inhaled corticosteroid per day were identified from the database of 1300 asthma volunteers held at the City Hospital, Nottingham and invited to take part in the study. Those who responded were contacted by telephone and an initial visit (visit 1) arranged at least 24 hours after the participant received the study information sheet. Ethical approval was granted by the local research ethics committee, City Hospital, Nottingham.

Inclusion criteria were a physician diagnosis of asthma with no deterioration of self-reported asthma symptoms for the previous month, use of at least one dose of inhaled steroid per day, bronchial reactivity to methacholine on two separate occasions, and the presence of atopy. Exclusion criteria were participation in other therapeutic studies in the previous 6 months, current smoking, a smoking history of more than 10 pack years, current use of oral corticosteroids, use of more than 2000 μg beclomethasone dipropionate (BDP) equivalent per day (1 μg BDP taken as equivalent to 1 μg budesonide or 0.5 μg fluticasone propionate), other serious illness, current or planned pregnancy within the study period, the use of vitamin E supplements within 3 months of screening, and a resting forced expiratory volume in 1 second (FEV1) of less than 1 litre. Participants who met these criteria and gave written consent were enrolled in the study.

Study design

The study was a double blind, randomised, placebo controlled study in adults with asthma of 6 weeks supplementation with vitamin E. Between visits 1 and 2 participants were asked to keep a baseline diary of peak flow measurements, symptom scores, and bronchodilator use for at least 2 weeks. At visit 2 those who had stable asthma, defined as no change in maintenance medication, underwent repeat bronchial reactivity and skin prick testing as at the screening visit to establish a baseline value and confirm eligibility for the study. Participants were given a diary to record peak expiratory flow rate and morning and evening symptoms scores. As far as possible all study visits took place at the same time of day in each individual, after abstaining from short acting bronchodilator inhalers for 4 hours, long acting bronchodilators for 12 hours, and antihistamines for 24 hours. Randomisation (in permuted blocks of six) and dispensing were carried out independently from the recruitment and assessment of participants, and the randomisation code was only broken at the end of the study. Participants were randomised to receive either two vitamin E capsules (250 mg natural vitamin E (α-tocopherol) in soya bean oil (R P Scherer Ltd, Swindon, UK) or two identical placebo...
Vitamin E supplements in asthma

Capsules (gelatine base) for 6 weeks. During the treatment period participants were asked to continue their diary of peak flow measurements, symptom scores, and bronchodilator use. At the end of the intervention period the participants attended for visit 3 and all the measures were repeated. All regular asthma medications including inhaled corticosteroids were continued to be taken at the same dose. Participants experiencing clinical exacerbation of asthma were treated as considered appropriate by their supervising physician including oral corticosteroids if required, returning to their regular pre-exacerbation medication use as soon as possible.

**Study measurements**

FEV₁ and forced vital capacity (FVC) were measured using a Vitalograph 2120 spirometer (Vitalograph, Buckingham, UK) according to the American Thoracic Society guidelines, taking the higher of two successive measurements within 200 ml for FEV₁ and the best of three technically satisfactory measures for FVC. Peak expiratory flow was recorded as the best of three measurements with a Mini-Wright peak flow meter (Clement Clarke, Harlow, UK) before medication in the morning and evening. Bronchial reactivity was defined as a dose of less than 12.25 μmol methacholine to cause a 20% fall in FEV₁ (PD₂₀) using the Yan method. Atopy was defined by at least one allergen skin test response (Der matophagoides pteronyssinus, cat fur, and grass pollen) 2 mm greater than control (lancets and allergens from Allergopharma Joachim Ganzer KG, Reinbek, Germany). Asthma symptoms for the night and day were scored on a scale from 0 (no symptoms) to 5 (incapacitating symptoms). Serum samples were taken for immunoglobulin E (IgE) (Pharmacia UniCap) and vitamin E. The samples for α-tocopherol analysis were extracted with hexane, prepared by drying down under nitrogen and redissolving in methanol, and then analysed by high performance liquid chromatography. Dietary data, including vitamin E, were assessed using a semi-quantitative food questionnaire (DietQ version 4.0CN, Tinuviel Software, Warrington, UK) at the baseline and final visits.

**Outcome measures**

The primary outcome was change in bronchial responsiveness to methacholine. Secondary outcomes were change in resting FEV₁, FVC, mean morning peak flow, symptom score, bronchodilator use (comparing the 2 week mean value before pre-exacerbation medication use as soon as possible.

**Statistical analysis and power**

Primary analysis was by intention to treat assuming a deterioration of two doubling doses (DD) in PD₂₀ in all participants withdrawing from the study or increasing treatment, and no change from baseline in secondary outcomes for the individual who withdrew before visit 3. The methacholine PD₂₀ values were log transformed for all analyses and expressed in terms of change in DD from baseline. PD₂₀ values above the upper limit of measurement (12.24 μmol methacholine) were censored at 12.24 μmol. A per protocol analysis was also performed, excluding all participants who failed to complete the protocol (those who withdrew or altered corticosteroid dosage). Each outcome was compared between treatment groups by the Student’s t test for parametric data and the Mann-Whitney U test for non-parametric data. Multiple linear regression was used to adjust for baseline differences in sex, baseline inhaled corticosteroid dose, baseline vitamin E intake, and baseline serum vitamin E. In addition, baseline vitamin E intake and serum vitamin E levels were divided above and below the median value and an interaction term was added by these variables to look for effect modification.

Our sample size of 35 individuals randomised to each of the vitamin E and placebo groups was chosen on the assumption of a within person standard deviation for change in bronchial reactivity of 2 DD and for FEV₁ of 250 ml in the placebo group, to provide 95% power to detect a difference of 1.7 DD in bronchial reactivity and 215 ml change in FEV₁ from baseline to a statistical level of significance of 0.05.

Statistical assessment was carried out with the Statistical Package for the Social Sciences (Version 11.5, SPSS Inc, Chicago, USA).

**RESULTS**

Participants were recruited between March and November 2002 with follow up through to January 2003. 72 subjects were randomised; 35 to receive vitamin E supplements and 37 to receive identical placebo (fig 1). Eight subjects did not complete the study per protocol (five vitamin E, three placebo) so were included in the intention to treat analysis but not per protocol analysis. Three participants in each group withdrew due to an exacerbation of their asthma. The characteristics of the vitamin E and placebo groups were similar at baseline including baseline vitamin E intake (table 1). Daily dietary vitamin E intake did not change significantly over the period of the study (p = 0.28).

At the end of the 6 week intervention period there was a significant increase in serum vitamin E levels in the treatment group (mean (SD) change +24.7 (12.8) μmol/l) compared with placebo (mean (SD) change +2.0 (5.5) μmol/l), resulting in a mean difference of +22.7 μmol/l (95% confidence interval CI +18.1 to +27.3).
Primary and secondary outcomes

In the intention to treat analysis there was no difference between those receiving vitamin E and those receiving placebo in change in bronchial reactivity to methacholine. The mean difference was +0.25 DD methacholine (95% CI −0.67 to +1.16) for the vitamin E group (mean (SD) +0.08 (2.33) DD) compared with placebo (mean (SD) −0.16 (1.50) DD). Adjusting for any one or all of the baseline parameters did not appreciably alter this result. Using intention to treat analysis there was no difference between the vitamin E and placebo groups in any of the secondary outcomes of change in FEV_{1}, FVC, morning peak flow, bronchodilator use, night time or day time symptom scores, serum IgE, or loss of atopic response (table 2).

In the per protocol analysis, excluding those who failed to complete or who increased or decreased treatment, there were also no significant differences between those who received vitamin E or placebo supplements in bronchial reactivity, change in FEV_{1}, FVC, morning peak flow, bronchodilator use, night time or day time symptom scores, serum IgE, or loss of atopic response (table 3). There were no significant interactions with baseline vitamin E intake or serum level in either the intention to treat or per protocol analyses.

DISCUSSION

The aim of this study was to determine whether dietary supplementation with vitamin E in adults with mild to moderate asthma using regular inhaled corticosteroids would result in an improvement in bronchial reactivity or other measures of asthma control. Our findings show that daily administration of 500 mg natural vitamin E for 6 weeks had no effect on asthma.

Our validation data suggest that adherence with allocated treatment was good, as shown by the 90% increase in serum vitamin E in this group. Our findings are also unlikely to be attributable to low study power. We determined our sample size to detect an improvement of 1.7 DD methacholine and, attributable to low study power. We determined our sample size to detect an improvement of 1.7 DD methacholine and, although the number who provided complete data was 64 (which was slightly less than the 70 participants needed according to our power calculation), this small difference in

Table 1 Baseline characteristics of study participants

<table>
<thead>
<tr>
<th>Outcome</th>
<th>All (n = 37)</th>
<th>Vitamin E group (n = 35)</th>
<th>Placebo group (n = 37)</th>
<th>Difference* (95% CI) p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) change in bronchial reactivity in doubling doses</td>
<td>+0.08 (2.33)</td>
<td>−0.16 (1.50)</td>
<td>+0.25 (−0.67 to +1.16)</td>
<td>0.59</td>
</tr>
<tr>
<td>Mean (SD) change in FEV_{1} (ml)</td>
<td>+37 (163)</td>
<td>−26 (203)</td>
<td>+63 (−24 to +149)</td>
<td>0.16</td>
</tr>
<tr>
<td>Mean (SD) change in FVC (ml)</td>
<td>+27 (194)</td>
<td>−18 (302)</td>
<td>+46 (−76 to +165)</td>
<td>0.46</td>
</tr>
<tr>
<td>Mean (SD) change in am peak flow (l/min)</td>
<td>+1 (24)</td>
<td>−4 (21)</td>
<td>+5 (−6 to +16)</td>
<td>0.36</td>
</tr>
<tr>
<td>Median (range) change in bronchodilator use (puffs/day)†</td>
<td>0 (−3 to +4)</td>
<td>0 (−8 to +5)</td>
<td>0*</td>
<td>0.49</td>
</tr>
<tr>
<td>Median (range) change in day time symptom score</td>
<td>0 (−1 to +1)</td>
<td>0 (−1 to 2)</td>
<td>0*</td>
<td>0.58</td>
</tr>
<tr>
<td>Median (range) change in night time symptom score</td>
<td>0 (−2 to +1)</td>
<td>0 (−1 to +2.5)</td>
<td>0*</td>
<td>0.93</td>
</tr>
<tr>
<td>Mean (SD) ratio of change in IgE</td>
<td>0.99 (1.22)</td>
<td>0.99 (1.54)</td>
<td>1.01 (0.86 to 1.18)</td>
<td>0.95</td>
</tr>
<tr>
<td>Loss of atopic response*</td>
<td>7/35 (20%)</td>
<td>5/37 (14%)</td>
<td>6% (−11 to 24)</td>
<td>0.46</td>
</tr>
</tbody>
</table>

Visit 3 data not available for one participant so baseline data used for visit 3.

FEV_{1} = forced expiratory volume in 1 second; FVC = forced vital capacity.

* Differences in log terms for IgE were anti-logged to give ratio of IgE values, final/baseline and vitamin E/placebo.
† Analysis by the Mann-Whitney U test with median change.
‡ Analysis by z test.
* Confidence intervals not calculated for difference in medians.

Visit 3 data not available for one participant so baseline data used for visit 3.
power is insufficient to invalidate the negative result of this study. We are, however, unable to exclude the possibility that vitamin E has an effect but of smaller magnitude, and our 95% confidence interval suggests that the true effect is unlikely to be greater than an increase of 1.16 DD in PD_{10}.

Our finding conflicts with the available epidemiological evidence and we need to consider why we did not see an effect of vitamin E supplements on asthma control. It is possible that vitamin E is effective only in those with a low dietary vitamin E intake. The daily vitamin E intake in our study population was only 10% less than the mean value for the UK,17 but restricting the analysis to those who consumed less than half the median intake for the study did not affect our findings. We therefore consider this explanation to be unlikely. It is possible that the observational epidemiological evidence suggesting that vitamin E may be important in the development of asthma18 has arisen from confounding by other associated nutrients and lifestyle exposures. In addition, dietary vitamin E is correlated with dietary vitamin C18 which is required to permit optimal antioxidant activity,19 and it may be that supplementation with vitamin E and vitamin C is required to see a beneficial effect on asthma control. This is supported by the intervention studies of vitamin E and vitamin C with 11 and without 10 β-carotene which have shown a beneficial effect on ozone induced bronchial hyperresponsiveness, the beneficial effect being seen in as little as 4 weeks.8 Although these findings suggest that the duration of our study was adequate, we also cannot exclude the possibility that a beneficial response may have become evident after a longer period of intervention. In addition, it is possible that studying a population of adults with asthma currently being treated with regular inhaled corticosteroids reduced our ability to detect an effect of vitamin E supplements, and we cannot discount the possibility that vitamin E may have an effect in steroid naive asthmatics. It is important to stress that our study subjects were non-smokers and so it is impossible to generalise our findings to those who are exposed to a larger exogenous oxidant burden either by cigarette smoking12 or exposure to higher levels of environmental ozone.20

The implication of our study is therefore that dietary supplementation of vitamin E for 6 weeks has no effect on asthma control. Since we have previously found a similar outcome for vitamin C and magnesium supplements in asthma,21 our trials indicate that these single nutrients are not effective. Future studies of antioxidants should therefore perhaps consider using combinations of antioxidants, whether in a synthetic preparation or in the form of whole foods such as fruit.

ACKNOWLEDGEMENTS
The authors thank Ms Sarah Pacey for dispensing the supplements and Dr Nigel Lawson for supervising the biochemical assays.

Authors’ affiliations
P J K Pearson, S A Lewis, A Fogarty, Division of Respiratory Medicine, University of Nottingham, Clinical Science Building, Nottingham City Hospital, Nottingham NG5 1PB, UK
J Britton, Division of Epidemiology and Public Health, University of Nottingham, Clinical Science Building, Nottingham City Hospital, Nottingham NG5 1PB, UK

Funding from National Asthma Campaign. The vitamin E tablets were provided by RP Scherer Ltd.

REFERENCES

Table 3 Per protocol analysis of change in primary and secondary outcome measures over 6 weeks in the vitamin E and placebo groups

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Vitamin E (n = 30)</th>
<th>Placebo (n = 34)</th>
<th>Difference* (95% CI) p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean (SD) change in bronchial reactivity* (DD)</td>
<td>+0.38 (2.38)</td>
<td>0.00 (1.45)</td>
<td>+0.38 (–0.59 to +1.35) 0.44</td>
</tr>
<tr>
<td>Mean (SD) change in FEV&lt;sub&gt;1&lt;/sub&gt; (ml)</td>
<td>+25 (138)</td>
<td>–27 (212)</td>
<td>+52 (–38 to +143) 0.25</td>
</tr>
<tr>
<td>Mean (SD) change in FVC (ml)</td>
<td>–25 (177)</td>
<td>–16 (313)</td>
<td>+41 (–88 to +170) 0.53</td>
</tr>
<tr>
<td>Mean (SD) change in AM peak</td>
<td>+1 (25)</td>
<td>–3 (21)</td>
<td>+4 (–7 to +16) 0.48</td>
</tr>
<tr>
<td>Mean (SD) change in FEV&lt;sub&gt;1&lt;/sub&gt; (%)</td>
<td>0 (–3 to +2)</td>
<td>0 (–8 to +5)</td>
<td>0* 0.65</td>
</tr>
<tr>
<td>Median (range) change in bronchodilator use (puffs/day)†</td>
<td>0 (–1 to +1)</td>
<td>0 (–1 to +2)</td>
<td>0* 0.68</td>
</tr>
<tr>
<td>Median (range) change in daytime symptom score</td>
<td>0 (–2 to +1)</td>
<td>0 (–2 to +2)</td>
<td>0* 0.92</td>
</tr>
<tr>
<td>Median (range) change in nighttime symptom score</td>
<td>0 (–2 to +1)</td>
<td>0 (–2 to +2)</td>
<td>0* 0.92</td>
</tr>
<tr>
<td>Mean (SD) change in IgE ratio</td>
<td>0.98 (1.24)</td>
<td>0.95 (1.54)</td>
<td>1.03 (0.87 to 1.23) 0.73</td>
</tr>
<tr>
<td>Loss of atopic response‡</td>
<td>7/30 (23%)</td>
<td>5/34 (15%)</td>
<td>9% (–10 to 28) 0.57</td>
</tr>
</tbody>
</table>

FEV<sub>1</sub> = forced expiratory volume in 1 second; FVC = forced vital capacity.
*Differences in log terms for IgE were anti-logged to give ratio of IgE values, final/baseline and vitamin E/placebo.
†Analysis by the Mann-Whitney U test with median change.
‡Analysis by χ<sup>2</sup> test.
*Confidence intervals not calculated for difference in medians.
The risk of developing chronic thromboembolic pulmonary hypertension (CTPH) following pulmonary embolism (PE) has not been clearly defined. In this prospective study 223 patients diagnosed with a first symptomatic PE were followed for a median period of 94.5 months. Patients with conditions predisposing to non-thromboembolic pulmonary hypertension were excluded from the study, as were those with a previous PE or deep vein thrombosis (DVT). Patients who developed unexplained breathlessness during follow up were investigated with transthoracic echocardiography, V/Q scanning and pulmonary angiography followed when echocardiography suggested CTPH. CTPH was diagnosed on the basis of pulmonary artery pressures and angiographic findings. Seven patients developed CTPH. The cumulative incidence of CTPH at 6 months was 1%, at 1 year 3.1%, and at 2 years 3.8%. No cases of CTPH presented more than 2 years after the initial diagnosis of PE.

A further 82 patients with acute PE and previous thromboembolism were included in an analysis of risk factors for CTPH; 11 of these patients developed CTPH. Risk factors included previous PE, or PE presenting at a younger age, with a larger perfusion defect, or in the absence of an identifiable risk factor.

This study suggests that CTPH occurs earlier and more frequently than previously estimated. As a serious and relatively common complication of PE, more attention should be focused on prevention, early detection, and treatment. Prevention of recurrent PE by improvements in the treatment of PE and DVT should reduce the incidence of CTPH.

**H C Barker**
Specialist Registrar, Basildon Hospital, Essex, UK; Barkerhc@yahoo.com

**Chronic thromboembolic pulmonary hypertension: an under-recognised consequence of PE**


The risk of developing chronic thromboembolic pulmonary hypertension (CTPH) following pulmonary embolism (PE) has not been clearly defined. In this prospective study 223 patients diagnosed with a first symptomatic PE were followed for a median period of 94.5 months. Patients with conditions predisposing to non-thromboembolic pulmonary hypertension were excluded from the study, as were those with a previous PE or deep vein thrombosis (DVT). Patients who developed unexplained breathlessness during follow up were investigated with transthoracic echocardiography, V/Q scanning and pulmonary angiography followed when echocardiography suggested CTPH. CTPH was diagnosed on the basis of pulmonary artery pressures and angiographic findings. Seven patients developed CTPH. The cumulative incidence of CTPH at 6 months was 1%, at 1 year 3.1%, and at 2 years 3.8%. No cases of CTPH presented more than 2 years after the initial diagnosis of PE.

A further 82 patients with acute PE and previous thromboembolism were included in an analysis of risk factors for CTPH; 11 of these patients developed CTPH. Risk factors included previous PE, or PE presenting at a younger age, with a larger perfusion defect, or in the absence of an identifiable risk factor.

This study suggests that CTPH occurs earlier and more frequently than previously estimated. As a serious and relatively common complication of PE, more attention should be focused on prevention, early detection, and treatment. Prevention of recurrent PE by improvements in the treatment of PE and DVT should reduce the incidence of CTPH.
Vitamin E supplements in asthma: a parallel group randomised placebo controlled trial

P J K Pearson, S A Lewis, J Britton and A Fogarty

Thorax 2004 59: 652-656
doi: 10.1136/thx.2004.022616

Updated information and services can be found at:
http://thorax.bmj.com/content/59/8/652

These include:

References
This article cites 20 articles, 8 of which you can access for free at:
http://thorax.bmj.com/content/59/8/652#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Asthma (1782)
- Airway biology (1100)
- Lung function (773)
- Clinical trials (epidemiology) (557)
- Drugs: respiratory system (526)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/